Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03406949 · ClinicalTrials.gov registry record · Phase 1
MGD009/MGA012 Combination in Relapsed/Refractory Cancer
A Phase 1 study, sponsored by MacroGenics.
- Completed
- Registry status
- Phase 1
- Development phase
- 25
- Enrollment target
NCT03406949 is a Phase 1 study that has completed, run by MacroGenics. The registered enrollment target is 25 participants.
The verdict
NCT03406949, a Phase 1 study, has completed, sponsored by MacroGenics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 25 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety and tolerability, pharmacokinetics (PK) pharmacodynamics and preliminary antitumor activity of obrindatamab administered in combination with retifanlimab in patients with B7-H3- expressing tumors.
Interventions
- BIOLOGICAL retifanlimab
- BIOLOGICAL obrindatamab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2018-02-27 |
| Est. Completion | 2022-04-27 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03406949
The ClinicalTrials.gov registry entry for NCT03406949 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is MacroGenics, which has 36 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which retifanlimab is the first listed.
NCT03406949 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03406949 about?
NCT03406949 is a clinical study titled "MGD009/MGA012 Combination in Relapsed/Refractory Cancer". The purpose of this study is to evaluate the safety and tolerability, pharmacokinetics (PK) pharmacodynamics and preliminary antitumor activity of obrindatamab administered in combination with retifanlimab in patients with B7-H3- expressing tumors.
What is the current status of trial NCT03406949?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 25 participants. The study started on 2018-02-27. Estimated completion is 2022-04-27.
What interventions are being tested in trial NCT03406949?
The interventions under investigation include: retifanlimab (BIOLOGICAL), obrindatamab (BIOLOGICAL).
Who is sponsoring clinical trial NCT03406949?
This trial is sponsored by MacroGenics, which has 36 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.